Susquehanna International Group, LLP Altimmune, Inc. Put Options Transaction History

Susquehanna International Group, LLP

9 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	BUY	$5.5 - $8.1 $414,700 - $610,740	75,400 Added 22.16%	415,600 $2.55 Million
Q2 2024 Aug 15, 2024	BUY	$5.91 - $10.23 $492,894 - $853,182	83,400 Added 32.48%	340,200 $2.26 Million
Q1 2024 May 07, 2024	SELL	$8.22 - $13.81 $1.77 Million - $2.98 Million	-215,800 Reduced 45.66%	256,800 $2.61 Million
Q4 2023 Feb 14, 2024	BUY	$2.14 - $11.62 $827,324 - $4.49 Million	386,600 Added 449.53%	472,600 $5.32 Million
Q3 2023 Nov 14, 2023	BUY	$2.4 - $3.45 $17,280 - $24,840	7,200 Added 9.14%	86,000 $223,000
Q2 2023 Aug 11, 2023	BUY	$3.45 - $5.97 $25,530 - $44,178	7,400 Added 10.36%	78,800 $278,000
Q1 2023 May 16, 2023	SELL	$4.19 - $16.83 $376,681 - $1.51 Million	-89,900 Reduced 55.73%	71,400 $301,000
Q4 2022 Feb 14, 2023	SELL	$8.74 - $16.45 $405,536 - $763,280	-46,400 Reduced 22.34%	161,300 $2.65 Million
Q3 2022 Nov 14, 2022	BUY	$10.67 - $22.41 $1.37 Million - $2.87 Million	128,000 Added 160.6%	207,700 $2.65 Million

185

39.2M

913K

743K

Ticker ALT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,025,300
Market Cap $373M
Description
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.